Interv Akut Kardiol. 2009;8(2):93-96

Prasugrel

Ivo Varvařovský
Kardio-Troll, pracoviště invazivní kardiologie, Krajská nemocnice, Pardubice

Purinergic system plays important role in cardiovascular regulation. In cardiology, antiplatelet effect of drugs with antagonistic effects

on P2Y12 receptor is frequently used. Prasugrel is the most potent indirect thienopyridine P2Y12 inhibitor and its position in current treatment

of acute coronary syndrome is discussed in this review article.

Keywords: prasugrel, thienopyridines.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Prasugrel. Interv Akut Kardiol. 2009;8(2):93-96.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purin Signalling 2008; 4: 1-20. Go to original source... Go to PubMed...
    2. Mega JL, Close SL, Wiviott SD. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: e-publication ahead of print. Go to original source... Go to PubMed...
    3. Hagihara K, Nishiya Y, Kurihara A. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel and ticlopidine. Drug Metab Pharmacokinet 2008; 23: 412-420. Go to original source... Go to PubMed...
    4. Sugidachi A, Asai F, Ogawa T. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Brit J Pharmacol 2000; 129: 1439-1446. Go to original source... Go to PubMed...
    5. Sugidachi A, Asai F, Yoneda K. Antiplatelet action of R-99224, an active metabolit of a novel thienopyridine-type G (i) - linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132: 47-54. Go to original source... Go to PubMed...
    6. Jakubowski JA, Matsushima N, Asai F. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2006; 63: 421-430. Go to original source... Go to PubMed...
    7. Wiviott SD, Antman EM, Winters KJ. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Circulation 2005; 111: 3366-3373. Go to original source... Go to PubMed...
    8. Wiviott SD, Braunwald E, McCabe CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.